BLAINJECTIONINJECTABLE
Approved
Mar 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
18
Data completeness
6/8 — Strong
CINQAIR (reslizumab) by Teva is interleukin-5 antagonists [moa]. Approved for eosinophilic asthma, asthma. First approved in 2016.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CINQAIR (reslizumab) is a monoclonal antibody that antagonizes interleukin-5, a key driver of eosinophil activation in inflammatory airway diseases. It is indicated for eosinophilic asthma, eosinophilic esophagitis, eosinophilic bronchitis, and oral corticosteroid-dependent asthma. The drug works by binding IL-5 and reducing circulating and tissue-resident eosinophils.
$0.956MPart D
PeakProduct is at peak lifecycle with modest spending, suggesting mature but niche market positioning requiring targeted commercial execution.
Mechanism of Action
Interleukin-5 Antagonists
Pharmacologic Class:
Interleukin-5 Antagonist
Indications (2)
Clinical Trials (18)
Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma
Started Feb 2021
10 enrolled
Asthma; Eosinophilic
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Started Sep 2017
10 enrolled
Asthma
An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation
Started May 2017
5 enrolled
Asthma
Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab
Started Apr 2017
30 enrolled
Severe Asthma
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Started Mar 2017
391 enrolled
Eosinophils, Asthma
Worked on CINQAIR at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.